On Jun. 1, 1989, the FDA approved Amgen’s Epogen/Procrit for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. On April 1, 1993 for the treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy.